CNBX Pharmaceuticals, Inc. is a clinical stage company, which engages in the discovery, development, and commercialization of cannabinoid-based products and technologies for the treatment of cancer. The company is headquartered in Bethesda, Maryland and currently employs 2 full-time employees. The company went IPO on 2007-07-02. The firm's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The firm indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.
Follow-Up Questions
Qui est le CEO de CNBX Pharmaceuticals Inc ?
Mr. Eyal Barad est le Chief Executive Officer de CNBX Pharmaceuticals Inc, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action CNBX ?
Le prix actuel de CNBX est de $0.0003, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de CNBX Pharmaceuticals Inc ?
CNBX Pharmaceuticals Inc appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de CNBX Pharmaceuticals Inc ?
La capitalisation boursière actuelle de CNBX Pharmaceuticals Inc est de $27752.999999999996
